1. Home
  2. LQDA vs LC Comparison

LQDA vs LC Comparison

Compare LQDA & LC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • LC
  • Stock Information
  • Founded
  • LQDA 2004
  • LC 2006
  • Country
  • LQDA United States
  • LC United States
  • Employees
  • LQDA N/A
  • LC N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • LC Finance: Consumer Services
  • Sector
  • LQDA Health Care
  • LC Finance
  • Exchange
  • LQDA Nasdaq
  • LC Nasdaq
  • Market Cap
  • LQDA 1.9B
  • LC 2.0B
  • IPO Year
  • LQDA 2018
  • LC 2014
  • Fundamental
  • Price
  • LQDA $23.15
  • LC $17.92
  • Analyst Decision
  • LQDA Strong Buy
  • LC Strong Buy
  • Analyst Count
  • LQDA 9
  • LC 6
  • Target Price
  • LQDA $32.67
  • LC $19.67
  • AVG Volume (30 Days)
  • LQDA 2.1M
  • LC 2.0M
  • Earning Date
  • LQDA 11-03-2025
  • LC 10-22-2025
  • Dividend Yield
  • LQDA N/A
  • LC N/A
  • EPS Growth
  • LQDA N/A
  • LC 91.85
  • EPS
  • LQDA N/A
  • LC 0.88
  • Revenue
  • LQDA $19,322,000.00
  • LC $1,296,102,000.00
  • Revenue This Year
  • LQDA $424.31
  • LC N/A
  • Revenue Next Year
  • LQDA $359.32
  • LC $15.53
  • P/E Ratio
  • LQDA N/A
  • LC $20.40
  • Revenue Growth
  • LQDA 30.20
  • LC 16.98
  • 52 Week Low
  • LQDA $9.71
  • LC $7.90
  • 52 Week High
  • LQDA $29.94
  • LC $19.88
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 48.99
  • LC 61.02
  • Support Level
  • LQDA $21.97
  • LC $16.04
  • Resistance Level
  • LQDA $24.34
  • LC $19.88
  • Average True Range (ATR)
  • LQDA 1.20
  • LC 0.82
  • MACD
  • LQDA 0.05
  • LC 0.26
  • Stochastic Oscillator
  • LQDA 40.98
  • LC 59.79

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About LC LendingClub Corporation

LendingClub Corp is a company engaged in operating an online lending marketplace platform that connects borrowers and investors for the provision of the loan facility. It offers investors access to an asset class that has generally been closed to many investors and only available on a limited basis to institutional investors. The company through the platform offers loan products such as personal, education and patient finance, small business, and auto to interested investors. It generates a majority of the revenue from the transaction fees received from the platform's role in accepting and decisioning applications on behalf of the bank partners to enable loan originations.

Share on Social Networks: